Physician profile
David Christopher Brooks
NPI 1043698046
$4,806.79
in general payments reported to CMS, 2019-2025
29 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $589 · 2023: $743 · 2024: $1,528 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,462.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $858.41 | 2021-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $746.33 | 2021-2025 | Provenge |
| Procept Biorobotics Corporation | $529.97 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $385.11 | 2021-2024 | Xtandi, Myrbetriq |
| Abbvie INC. | $287.58 | 2022-2025 | |
| Teleflex LLC | $257.64 | 2021-2024 | Urolift |
| Pfizer INC. | $236.38 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.91 | 2021-2025 | |
| Axonics, INC. | $148.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $142.01 | 2024-2025 | |
| Calyxo, INC. | $122.02 | 2022-2025 | Cvac Aspiration System |
| Immunitybio, INC. | $118.90 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $115.05 | 2024 | Lynparza |
| Sumitomo Pharma America, INC. | $103.10 | 2024-2025 | Orgovyx |
| Blue Earth Diagnostics | $67.78 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.10 | 2022-2023 | |
| Bioprotect Medical, INC. | $57.81 | 2025 | Bioprotect Balloon Implant System |
| Myriad Genetic Laboratories, INC. | $56.53 | 2022-2023 | Prolaris |
| Urovant Sciences INC | $47.42 | 2021-2022 | |
| Tolmar, INC. | $42.71 | 2023-2024 | |
| Telix Pharmaceuticals | $42.20 | 2024 | Illuccix |
| Kowa Pharmaceuticals America, INC. | $31.85 | 2023 | Seglentis |
| Acerus Pharmaceuticals Corporation | $29.72 | 2021 | |
| Boston Scientific Corporation | $24.79 | 2024 | Rezum Generator |
| Myovant Sciences INC. | $18.09 | 2021 | |
| Genzyme Corporation | $17.74 | 2022 | |
| Urogen Pharma, INC. | $17.17 | 2025 | |
| Olympus America INC. | $16.73 | 2025 | Itind System |
| Janssen Scientific Affairs, LLC | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.